Delving into the Latest Updates on Protherics Plc with Synapse

Overview

Tags

Other Diseases

Antitoxin

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Antitoxin	1

2131 Background: To determine the systemic plasma levels, safety and maximum tolerated dose (MTD) of a depot formulation of paclitaxel, OncoGel (paclitaxel/ReGel). This is a cremophor-free formulation which is liquid at administration temperature and rapidly forms a gel depot upon injection. The depot slowly degrades over several weeks allowing controlled release of paclitaxel within the tumor. Methods: A Phase I, dose-escalation study was conducted in 16 end-stage cancer patients with 18 superficially accessible solid malignant lesions at 6 investigative sites. Four paclitaxel dosages based on tumor volume were administered with 3 patients receiving 0.06 mg/cm3, 3 patients at 0.24 mg/cm3, 6 patients with 8 tumors at 0.48 mg/cm3, and 4 patients at 1.92 mg/cm3. There were 7 females and 9 males, ages 41 to 89, with treated tumors ranging from 0.7 cm3 to 19.0 cm3. The primary diagnoses included lymphoma, melanoma, lung, head and neck, laryngeal, thyroid, and breast cancer. Results: Blood samples were collect...

01 Oct 2000·Biochemical Society Transactions

High Affinity, Slow Binding FXa Inhibitors Are Poor Inhibitors Of Clot Formation in vitro

Author: Dyas, S ; Martin, H ; Liebeschuetz, J ; Mahler, J ; Auton, T

01 Mar 2000·Journal of Chemical Information and Computer Sciences

New Approach to Molecular Docking and Its Application to Virtual Screening of Chemical Databases

Article

Author: Perkins, Tim D. J. ; Li, Jin ; Bone, Richard G. A. ; Murray, Christopher W. ; Waszkowycz, Bohdan ; Wylie, William ; Sykes, Richard A. ; Baxter, Carol A.

This paper describes the validation of a molecular docking method and its application to virtual database screening. The code flexibly docks ligand molecules into rigid receptor structures using a tabu search methodology driven by an empirically derived function for estimating the binding affinity of a protein-ligand complex. The docking method has been tested on 70 ligand-receptor complexes for which the experimental binding affinity and binding geometry are known. The lowest energy geometry produced by the docking protocol is within 2.0 A root mean square of the experimental binding mode for 79% of the complexes. The method has been applied to the problem of virtual database screening to identify known ligands for thrombin, factor Xa, and the estrogen receptor. A database of 10,000 randomly chosen "druglike" molecules has been docked into the three receptor structures. In each case known receptor ligands were included in the study. The results showed good separation between the predicted binding affinities of the known ligand set and the database subset.

2

News (Medical) associated with Protherics Plc

31 Mar 2008

·www.biospace.com

Encorium Group, Inc. Announces $1.6 Million Contract for a Phase 2 Trial of an Innovative Immunotherapeutic Vaccine for the Treatment of Hypertension

WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO - News), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies today announced the signing of a $1.6 million contract with Protherics, a leading UK biopharmaceutical company, for a Phase 2 trial of its novel immunotherapeutic vaccine, Angiotensin Therapeutic Vaccine (ATV), for the treatment of hypertension.

Vaccine

22 May 2007

·www.biospace.com

Protherics PLC Release: VoraxazeTM Update

London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today provided an update on its VoraxazeTM marketing applications in the US and EU. VoraxazeTM is an adjunctive therapy for patients with impaired renal function who are experiencing, or at risk of, toxicity from methotrexate ("MTX"), a widely used anti-cancer agent.

100 Deals associated with Protherics Plc

Login to view more data

100 Translational Medicine associated with Protherics Plc

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Antivenom PolongaTAb (Protherics)	Snake Bites More	Clinical
Polyclonal antibody TriTAb(Protherics Plc)	Poisoning More	Discontinued
NISV	Rheumatoid Arthritis More	Discontinued
Anti-gonadotrophin releasing hormone vaccine(Protherics Plc) ( GnRHR )	Prostatic Cancer More	Discontinued
AZD-9773(BTG Ltd.) ( TNF-α )	Coronary Disease More	Discontinued